Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence?Ekim Ekinci, Meghana V. Trivedi, Salima Nathoo et al.|Journal of Cancer Survivorship|2018Cited by 72
Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapyElisabeth M. Sulaica, Polly Niravath, Meghana V. Trivedi et al.|Breast Cancer Research and Treatment|2016Cited by 31
The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysisTran Do, Meghana V. Trivedi, Rohan Medhekar et al.|Breast Cancer Research and Treatment|2015Cited by 28
Challenges of measuring accurate estradiol levels in aromatase inhibitor‐treated postmenopausal breast cancer patients on vaginal estrogen therapyPolly Niravath, Meghana V. Trivedi, Raksha R. Bhat et al.|Pharmacology Research & Perspectives|2017Cited by 7
The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the adjuvant docetaxel and cyclophosphamide in patients with early-stage breast cancer: A meta-analysis.Tran Do, Meghana V. Trivedi, Polly Niravath|Journal of Clinical Oncology|2015Cited by 0